Stan­ford spin­out racks up more sup­port for its mR­NA ap­proach to cel­lu­lar re­ju­ve­na­tion

As the once-niche field of cel­lu­lar re­ju­ve­na­tion finds it­self un­der the spot­light on the an­ti-ag­ing stage — thanks in no small part to Al­tos Labs’ $3 bil­lion launch, quick­ly fol­lowed by the un­veil­ing of oth­er ef­forts — an­oth­er play­er is get­ting some love from in­ter­na­tion­al phar­ma in­vestors.

Turn Biotech­nolo­gies has closed a fi­nanc­ing round af­ter rais­ing an un­spec­i­fied amount of cash, with the lat­est in­fu­sion com­ing from South Ko­rea’s Dae­woong Phar­ma­ceu­ti­cal and HanAll Bio­phar­ma. Ex­ist­ing in­vestors in­clude Astel­las’ ven­ture arm and Khosla Ven­tures.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER